Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of lymphoid malignancies that portend a poor prognosis and have an undefined optimal therapeutic strategy. Data on best practices stem from prior studies that have generally included B cell lymphomas. However, the enhanced ability to diagnose PTCLs, the development of newer agents specific for PTCLs, and its increased incidence have called the scientific community to develop better strategies to combat these neoplasms. To that end, T cell lymphoma registries were developed in an attempt to answer relevant questions on the prognosis and management of PTCLs. The largest registries currently enrolling patients are the Comprehesive Oncology Measures for PeripheraL T-cEll Lymphoma TrEatment (COMPLETE) and the T-Cell Project. Despite the inherent limitations of these studies, valuable information are being collected to refine our management approaches and to aid in designing future clinical trials. This review illustrates the value of these registries and describes the critical questions that need to be answered.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11899-015-0291-0 | DOI Listing |
J Hematop
January 2025
Cleveland Clinic Florida, Weston, USA.
A 56-year-old male presented to the clinic with complaints of multiple skin lesions. A complete blood count (CBC) was not available. No constitutional symptoms were present, and physical examination revealed tender skin lesions of the back, arms, legs, and scalp.
View Article and Find Full Text PDFEur J Haematol
January 2025
Department of Research & Development, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.
Comprehensive insights are lacking into why patients with hematological malignancies (HMs) receive no cancer-directed treatment. We evaluated socio-demographic and cancer-related characteristics, decision-making rationales, and overall survival in patients with three common HMs-diffuse large B-cell lymphoma (DLBCL), symptomatic multiple myeloma (MM), and acute myeloid leukemia (AML)-who do not receive cancer-directed treatment, using the nationwide Netherlands Cancer Registry. A total of 26 945 patients diagnosed with DLBCL (47%), symptomatic MM (29%), or AML (25%) between 2014 and 2021 were included.
View Article and Find Full Text PDFUnited European Gastroenterol J
January 2025
Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
J Cell Mol Med
February 2025
Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Mucosa-associated lymphoid tissue (MALT) lymphoma is an extranodal low-grade non-Hodgkin lymphoma that extremely rarely localises to the mediastinum. A 34-year-old female with chronic arthralgia, sicca and rash was found to have a well-demarcated mediastinal cystic mass with equivocal nodular enhancement within the cystic wall on chest CT during a workup for Sjögren's syndrome. Subsequent Ga-Pentixafor-PET/CT revealed focal uptake increase within the cystic capsule.
View Article and Find Full Text PDFJ Cutan Med Surg
January 2025
Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!